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BACKGROUND
In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) 
reduce the risk of a first hospitalization for heart failure, possibly through glucose-
independent mechanisms. More data are needed regarding the effects of SGLT2 in-
hibitors in patients with established heart failure and a reduced ejection fraction, 
regardless of the presence or absence of type 2 diabetes.
METHODS
In this phase 3, placebo-controlled trial, we randomly assigned 4744 patients with 
New York Heart Association class II, III, or IV heart failure and an ejection fraction 
of 40% or less to receive either dapagliflozin (at a dose of 10 mg once daily) or pla-
cebo, in addition to recommended therapy. The primary outcome was a composite 
of worsening heart failure (hospitalization or an urgent visit resulting in intravenous 
therapy for heart failure) or cardiovascular death.
RESULTS
Over a median of 18.2 months, the primary outcome occurred in 386 of 2373 pa-
tients (16.3%) in the dapagliflozin group and in 502 of 2371 patients (21.2%) in 
the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.85; 
P<0.001). A first worsening heart failure event occurred in 237 patients (10.0%) in 
the dapagliflozin group and in 326 patients (13.7%) in the placebo group (hazard 
ratio, 0.70; 95% CI, 0.59 to 0.83). Death from cardiovascular causes occurred in 
227 patients (9.6%) in the dapagliflozin group and in 273 patients (11.5%) in the 
placebo group (hazard ratio, 0.82; 95% CI, 0.69 to 0.98); 276 patients (11.6%) and 
329 patients (13.9%), respectively, died from any cause (hazard ratio, 0.83; 95% CI, 
0.71 to 0.97). Findings in patients with diabetes were similar to those in patients 
without diabetes. The frequency of adverse events related to volume depletion, renal 
dysfunction, and hypoglycemia did not differ between treatment groups.
CONCLUSIONS
Among patients with heart failure and a reduced ejection fraction, the risk of wors-
ening heart failure or death from cardiovascular causes was lower among those who 
received dapagliflozin than among those who received placebo, regardless of the 
presence or absence of diabetes. (Funded by AstraZeneca; DAPA-HF ClinicalTrials 
.gov number, NCT03036124.)
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L arge clinical trials involving pa-tients with type 2 diabetes have shown that inhibitors of sodium–glucose cotransporter 
2 (SGLT2) reduce the risk of hospitalization for 
heart failure.1-4 Most patients in these trials did 
not have heart failure at baseline, so the benefit 
of treatment with an SGLT2 inhibitor largely re-
flected the prevention of incident heart failure. 
The reduction in the risk of hospitalization for 
heart failure was observed early after randomiza-
tion, which raised the possibility of mechanisms 
of action that differed from those usually postu-
lated to explain the cardiovascular benefits of 
glucose-lowering therapies.5-9 In addition to di-
uretic and related hemodynamic actions of SGLT2 
inhibitors, effects on myocardial metabolism, ion 
transporters, fibrosis, adipokines, and vascular 
function have also been proposed.5-9 These actions, 
along with preservation of renal function, would 
also benefit patients with established heart fail-
ure, including those without diabetes, in whom 
SGLT2 inhibitors have not been tested.4,10,11 We 
designed the DAPA-HF (Dapagliflozin and Pre-
vention of Adverse Outcomes in Heart Failure) 
trial to prospectively evaluate the efficacy and 
safety of the SGLT2 inhibitor dapagliflozin in 
patients with heart failure and a reduced ejection 
fraction, regardless of the presence or absence of 
diabetes.12,13
Me thods
Trial Design and Oversight
The executive committee designed and oversaw the 
conduct and analysis of the trial in collaboration 
with the sponsor, AstraZeneca.12,13 The trial was 
conducted and reported in accordance with the 
protocol and the statistical analysis plan, both of 
which are available with the full text of this ar-
ticle at NEJM.org. The trial was approved by the 
ethics committee at each center. The safety of 
patients in the trial was overseen by an indepen-
dent data and safety monitoring committee. The 
analyses conducted by the sponsor were replicated 
by an independent academic group at the Univer-
sity of Glasgow. The first draft of the manuscript 
was prepared by the first author, who had unre-
stricted access to the data, and was reviewed and 
edited by all the authors. All the authors made the 
decision to submit the manuscript for publication 
and vouch for the accuracy and completeness of 
the data and for the fidelity of the trial to the 
protocol.
Patients
Eligibility requirements included an age of at least 
18 years, an ejection fraction of 40% or less, and 
New York Heart Association (NYHA) class II, III, 
or IV symptoms. Patients were required to have 
a plasma level of N-terminal pro–B-type natriuretic 
peptide (NT-proBNP) of at least 600 pg per mil-
liliter (or ≥400 pg per milliliter if they had been 
hospitalized for heart failure within the previous 
12 months). Patients with atrial fibrillation or 
atrial flutter on baseline electrocardiography were 
required to have an NT-proBNP level of at least 
900 pg per milliliter, regardless of their history 
of hospitalization for heart failure.
Patients were required to receive standard heart-
failure device therapy (an implantable cardiovert-
er–defibrillator, cardiac resynchronization thera-
py, or both) and standard drug therapy, including 
an angiotensin-converting–enzyme inhibitor, an 
angiotensin-receptor blocker, or sacubitril–valsar-
tan plus a beta-blocker, unless such use was con-
traindicated or resulted in unacceptable side ef-
fects. In addition, the use of a mineralocorticoid 
receptor antagonist was encouraged. Drug doses 
were individually tailored, in accordance with 
guideline recommendations. Patients with type 
2 diabetes continued to take their glucose-lowering 
therapies, but doses could be adjusted as required. 
Specifically, the dose of insulin and sulfonylurea 
could be reduced to minimize the risk of hypo-
glycemia (e.g., in patients with a glycated hemo-
globin level of <7%).
Exclusion criteria included recent treatment 
with or unacceptable side effects associated with 
an SGLT2 inhibitor, type 1 diabetes mellitus, 
symptoms of hypotension or a systolic blood pres-
sure of less than 95 mm Hg, and an estimated 
glomerular filtration rate (eGFR) below 30 ml per 
minute per 1.73 m2 of body-surface area (or rap-
idly declining renal function).
Trial Procedures
All the patients provided written informed consent 
and entered a 14-day screening period, during 
which the trial inclusion and exclusion criteria 
were checked and baseline information gathered. 
After this screening, patients were randomly as-
signed to receive either dapagliflozin (at a dose of 
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10 mg once daily) or matching placebo, in accor-
dance with the sequestered, fixed-randomization 
schedule, with the use of balanced blocks to en-
sure an approximate 1:1 ratio of the two regimens. 
Investigators used an interactive voice- or Web-
response system to determine treatment assign-
ment. Randomization was stratified on the basis 
of a diagnosis of type 2 diabetes (i.e., an estab-
lished diagnosis or a glycated hemoglobin level 
of ≥6.5% [≥48 mmol per mole]) confirmed at 
screening.
Patients were evaluated at 14 days and 60 days 
after randomization, with a focus on assessment 
of heart failure and volume status, adverse events, 
and an evaluation of renal function and potassi-
um levels. Additional trial visits were scheduled 
at 4 months and at 4-month intervals thereafter 
(Fig. S1 in the Supplementary Appendix, avail-
able at NEJM.org). The full schedule of assess-
ments is provided in the trial protocol. Dapa-
glif lozin or placebo was to be discontinued if 
pregnancy or diabetic ketoacidosis occurred. Dose 
reduction (to 5 mg daily of dapagliflozin or pla-
cebo) or temporary discontinuation was permitted 
in case of an acute, unexpected decline in the 
eGFR, volume depletion, or hypotension (or to 
avoid these conditions), with a subsequent increase 
in dose or restarting of treatment, if possible.
Outcomes
The primary outcome was a composite of wors-
ening heart failure or death from cardiovascular 
causes. An episode of worsening heart failure 
was either an unplanned hospitalization or an 
urgent visit resulting in intravenous therapy for 
heart failure.
A key secondary outcome was a composite of 
hospitalization for heart failure or cardiovascular 
death. The additional secondary outcomes were 
the total number of hospitalizations for heart fail-
ure (including repeat admissions) and cardiovascu-
lar deaths; the change from baseline to 8 months 
in the total symptom score on the Kansas City 
Cardiomyopathy Questionnaire, which is scored 
Figure 1. Enrollment and Follow-up.
All the patients who underwent randomization were included in the primary analysis. Patients who did not receive a 
dose of either dapagliflozin or placebo were excluded from the safety analysis.
4744 Underwent randomization
8134 Patients underwent screening
3390 Were excluded
12 Died 
15 Had an adverse event
84 Declined to participate
3279 Did not meet eligibility criteria
5 Did not receive dapagliflozin 3 Did not receive placebo
2373 Were assigned to receive
dapagliflozin
2371 Were assigned to receive
placebo
249 Discontinued dapagliflozin
14 Had incomplete follow-up for the
primary outcome
258 Discontinued placebo
20 Had incomplete follow-up for the
primary outcome
2 Had unknown vital status
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on a scale from 0 to 100, with a higher score 
indicating fewer symptoms and a change of 5 or 
more points considered to be clinically mean-
ingful14; a composite of worsening renal func-
tion, which was defined as a sustained decline 
in the eGFR of 50% or greater, end-stage renal 
disease (defined as a sustained [≥28 days] eGFR 
of <15 ml per minute per 1.73 m2, sustained 
dialysis, or renal transplantation), or renal death; 
and death from any cause.12 All outcomes were 
adjudicated by the members of a clinical-events 
committee, who were unaware of trial-group 
Characteristic
Dapagliflozin 
(N = 2373)
Placebo 
(N = 2371)
Age — yr 66.2±11.0 66.5±10.8
Female sex — no. (%) 564 (23.8) 545 (23.0)
Body-mass index† 28.2±6.0 28.1±5.9
Race — no. (%)‡
White 1662 (70.0) 1671 (70.5)
Black 122 (5.1) 104 (4.4)
Asian 552 (23.3) 564 (23.8)
Other 37 (1.6) 32 (1.3)
Region — no. (%)
North America 335 (14.1) 342 (14.4)
South America 401 (16.9) 416 (17.5)
Europe 1094 (46.1) 1060 (44.7)
Asia–Pacific 543 (22.9) 553 (23.3)
NYHA functional classification — no. (%)
II 1606 (67.7) 1597 (67.4)
III 747 (31.5) 751 (31.7)
IV 20 (0.8) 23 (1.0)
Heart rate — beats/min 71.5±11.6 71.5±11.8
Systolic blood pressure — mm Hg 122.0±16.3 121.6±16.3
Left ventricular ejection fraction — % 31.2±6.7 30.9±6.9
Median NT-proBNP (IQR) — pg/ml 1428 (857–2655) 1446 (857–2641)
Principal cause of heart failure — no. (%)
Ischemic 1316 (55.5) 1358 (57.3)
Nonischemic 857 (36.1) 830 (35.0)
Unknown 200 (8.4) 183 (7.7)
Medical history — no. (%)
Hospitalization for heart failure 1124 (47.4) 1127 (47.5)
Atrial fibrillation 916 (38.6) 902 (38.0)
Diabetes mellitus§ 993 (41.8) 990 (41.8)
Estimated GFR
Mean — ml/min/1.73 m2 66.0±19.6 65.5±19.3
Rate of <60 ml/min/1.73 m2 — no./total no. (%) 962/2372 (40.6) 964/2371 (40.7)
Device therapy — no. (%)
Implantable cardioverter–defibrillator¶ 622 (26.2) 620 (26.1)
Cardiac resynchronization therapy‖ 190 (8.0) 164 (6.9)
Table 1. Characteristics of the Patients at Baseline.*
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assignments, according to prespecified criteria 
(with definitions listed in the Supplementary 
Appendix).15
The prespecified safety analyses included se-
rious adverse events, adverse events associated 
with the discontinuation of a trial treatment, 
adverse events of interest (i.e., volume depletion, 
renal events, major hypoglycemic events, bone 
fractures, diabetic ketoacidosis, and amputations), 
a diagnosis of Fournier’s gangrene, and labora-
tory findings of note. Data on other adverse 
events were not routinely collected in view of the 
extensive previous collection of safety data re-
garding dapagliflozin.3
Statistical Analysis
We calculated that 844 primary outcome events 
would provide the trial with a power of 90% to 
detect a hazard ratio of 0.80 for the comparison 
between dapagliflozin and placebo, using a two-
sided alpha level of 0.05. With an expected an-
nual event incidence of 11% in the placebo group, 
we estimated that the enrollment of approximately 
4500 patients would provide the required num-
ber of primary events, based on an anticipated 
recruitment period of 18 months and an average 
follow-up period of approximately 24 months. 
We used a closed testing procedure, with pre-
specified hierarchical testing of the primary and 
secondary outcomes. The type I error was con-
trolled at a two-sided alpha level of 0.0499 for 
multiple comparisons across primary and second-
ary outcomes, with one interim efficacy analysis 
taken into account.
We included data from all the patients who 
had undergone randomization in the analyses of 
the primary and secondary outcomes, according 
to the intention-to-treat principle. Baseline char-
acteristics were summarized as means and stan-
dard deviations, medians and interquartile ranges, 
Characteristic
Dapagliflozin 
(N = 2373)
Placebo 
(N = 2371)
Heart failure medication — no. (%)
Diuretic 2216 (93.4) 2217 (93.5)
ACE inhibitor 1332 (56.1) 1329 (56.1)
ARB 675 (28.4) 632 (26.7)
Sacubitril–valsartan 250 (10.5) 258 (10.9)
Beta-blocker 2278 (96.0) 2280 (96.2)
Mineralocorticoid receptor antagonist 1696 (71.5) 1674 (70.6)
Digitalis 445 (18.8) 442 (18.6)
Glucose-lowering medication — no./total no. (%)**
Biguanide 504/993 (50.8) 512/990 (51.7)
Sulfonylurea 228/993 (23.0) 210/990 (21.2)
DPP-4 inhibitor 161/993 (16.2) 149/990 (15.1)
GLP-1 receptor agonist 11/993 (1.1) 10/990 (1.0)
Insulin 274/993 (27.6) 266/990 (26.9)
*  Plus–minus values are means ±SD. There were no significant differences between the two groups for any variable. 
Percentages may not total 100 because of rounding. ACE denotes angiotensin-converting enzyme, ARB angiotensin-
receptor blocker, DPP-4 dipeptidyl peptidase 4, GFR glomerular filtration rate, GLP-1 glucagon-like peptide 1, IQR in-
terquartile range, NT-proBNP N-terminal pro–B-type natriuretic peptide, and NYHA New York Heart Association.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  Race was reported by the investigators.
§  An additional 82 patients in the dapagliflozin group and 74 in the placebo group had previously undiagnosed diabe-
tes, which was defined as a glycated hemoglobin level of 6.5% or greater (≥48 mmol per mole), as measured in a 
central laboratory at both screening and randomization.
¶  This category includes either an implantable cardioverter–defibrillator or cardiac resynchronization therapy with a de-
fibrillator.
‖  This category includes cardiac resynchronization therapy with or without a defibrillator.
**  Glucose-lowering medications are listed only for the patients who had a history of diabetes at baseline.
Table 1. (Continued.)
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or percentages. We used a mixed model for re-
peated measurement to analyze longitudinal mea-
sures (e.g., glycated hemoglobin level and body 
weight) and estimated the least-squares mean dif-
ferences between treatment groups, together with 
95% confidence intervals. Time-to-event data were 
evaluated with the use of Kaplan–Meier estimates 
and Cox proportional-hazards models, stratified 
according to diabetes status, with a history of hos-
pitalization for heart failure and treatment-group 
assignment as fixed-effect factors; for the renal 
outcome, the baseline eGFR was included instead 
of a history of hospitalization for heart failure. 
We used the Cox models to calculate hazard ratios, 
95% confidence intervals, and two-sided P values 
and used a semiparametric proportional-rates 
model to calculate total (including recurrent) 
events.16
We analyzed the total symptom score on the 
Kansas City Cardiomyopathy Questionnaire as a 
composite, rank-based outcome, incorporating 
patient vital status at 8 months along with a 
change in score from baseline to 8 months in 
surviving patients, using the rank analysis of 
covariance method, with a corresponding win 
ratio used to estimate the magnitude of treatment 
effect.17 We assessed the consistency of the treat-
ment effect among 14 prespecified subgroups. 
The safety analyses were performed in patients 
who had undergone randomization and received 
at least one dose of dapagliflozin or placebo. We 
used Fisher’s exact test to compare the incidence 
of adverse events. All the analyses were per-
formed with the use of Stata software, version 15 
(StataCorp) and R, version 3.5.1 (R Foundation for 
Statistical Computing).
R esult s
Patients
From February 15, 2017, through August 17, 2018, 
a total of 4744 patients were randomly assigned 
to receive either dapagliflozin or matching pla-
cebo at 410 centers in 20 countries (Fig. 1). The 
characteristics of the patients and the therapies 
for heart failure were well balanced between the 
trial groups at baseline (Table 1). At screening, 
42% of the patients in each trial group had a 
history of type 2 diabetes, and an additional 3% 
of the patients in each group received a new di-
agnosis of diabetes.
Dapagliflozin was stopped for reasons other 
than death in 249 patients and placebo was 
stopped in 258 patients (10.5% vs. 10.9%, P = 0.71). 
At the last assessment, 2039 of the patients who 
were still taking dapagliflozin (98.1%) continued 
to receive the 10-mg daily dose; 1993 patients 
(98.2%) were receiving the equivalent dose of 
placebo. No patients in the dapagliflozin group 
and 2 patients in the placebo group had un-
known vital status at the end of the trial (Fig. 1). 
The median duration of follow-up was 18.2 months 
(range, 0 to 27.8).
Outcomes
The primary composite outcome of worsening 
heart failure (hospitalization or an urgent visit 
resulting in intravenous therapy for heart failure) 
or death from cardiovascular causes occurred in 
386 patients (16.3%) in the dapagliflozin group 
and in 502 patients (21.2%) in the placebo group 
(hazard ratio, 0.74; 95% confidence interval [CI], 
0.65 to 0.85; P<0.001) (Table 2 and Fig. 2A).
Event rates for all three components of the 
composite outcome favored dapagliflozin; the larg-
est number of events of worsening heart failure 
were hospitalizations. Of the patients receiving 
dapagliflozin, 231 (9.7%) were hospitalized for 
heart failure, as compared with 318 patients 
(13.4%) receiving placebo (hazard ratio, 0.70; 95% 
CI, 0.59 to 0.83) (Fig. 2B). Death from cardiovas-
cular causes occurred in 227 patients (9.6%) who 
received dapagliflozin and in 273 (11.5%) who 
received placebo (hazard ratio, 0.82; 95% CI, 
0.69 to 0.98) (Fig. 2C). During the trial period, 
the number of patients who would need to have 
been treated with dapagliflozin to prevent one 
primary event was 21 (95% CI, 15 to 38).
The incidence of the secondary composite 
outcome of hospitalization for heart failure or 
death from cardiovascular causes was lower in 
the dapagliflozin group than in the placebo 
group (hazard ratio, 0.75; 95% CI, 0.65 to 0.85; 
P<0.001) (Table 2). There were 567 total first and 
recurrent events (340 hospitalizations for heart 
failure and 227 deaths from cardiovascular causes 
in 382 patients) in the dapagliflozin group and 
742 total events (469 hospitalizations for heart 
failure and 273 deaths from cardiovascular causes 
in 495 patients) in the placebo group, which re-
sulted in a rate ratio of 0.75 (95% CI, 0.65 to 0.88; 
P<0.001).
The increase in the total symptom score on 
the Kansas City Cardiomyopathy Questionnaire 
The New England Journal of Medicine 
Downloaded from nejm.org at GLASGOW UNIVERSITY LIBRARY on September 20, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 10
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
(indicating fewer symptoms) was greater in the 
dapagliflozin group than in the placebo group 
between baseline and month 8 (Table 2). More 
patients in the dapaglif lozin group than in the 
placebo group had an increase of at least 5 points 
(the minimally important difference) in the total 
score (58.3% vs. 50.9%; odds ratio, 1.15; 95% CI, 
1.08 to 1.23) and fewer had significant deterio-
ration (25.3% vs. 32.9%; odds ratio, 0.84; 95% 
CI, 0.78 to 0.90; P<0.001 for both comparisons). 
The incidence of the prespecified renal compos-
ite outcome did not differ between the treatment 
groups (Table 2).
A total of 276 patients (11.6%) in the dapa-
gliflozin group and 329 patients (13.9%) in the 
placebo group died from any cause (hazard ratio, 
0.83; 95% CI, 0.71 to 0.97) (Fig. 2D). Details re-
garding the analysis of deaths and hospitalizations 
for heart failure are summarized in Figure S2.
The effect of dapagliflozin on the primary 
outcome was generally consistent across pre-
specified subgroups, including in patients with-
out diabetes at baseline, although the patients in 
NYHA functional class III or IV appeared to have 
less benefit than those in class II (Fig. 3). In a 
post hoc subgroup analysis involving patients 
taking sacubitril–valsartan at baseline, the haz-
ard ratio for the comparison of dapagliflozin 
and placebo for the primary outcome was 0.75 
(95% CI, 0.50, 1.13), as compared with 0.74 (95% 
CI, 0.65 to 0.86) among those not taking sacubi-
tril–valsartan.
Changes from baseline to 8 months in values 
for glycated hemoglobin, hematocrit, creatinine, 
NT-proBNP, systolic blood pressure, and weight 
are shown in Table 2.
Safety
A total of 8 patients (5 in the dapagliflozin 
group and 3 in the placebo group) were excluded 
from the safety analyses because they did not 
receive dapagliflozin or placebo (Table 2). Seri-
ous adverse events related to volume depletion 
occurred in 29 patients (1.2%) in the dapa-
gliflozin group and in 40 patients (1.7%) in the 
placebo group (P = 0.23). Serious renal adverse 
events occurred in 38 patients (1.6%) in the 
dapagliflozin group and in 65 patients (2.7%) in 
the placebo group (P = 0.009). Adverse events 
rarely led to a discontinuation of treatment. All 
serious adverse events are listed in Table S1; 
there was no notable excess of any event in the 
dapagliflozin group.
Discussion
In this randomized, placebo-controlled trial in-
volving patients with heart failure and a reduced 
left ventricular ejection fraction, the risk of the 
primary composite outcome of worsening heart 
failure (hospitalization or an urgent visit result-
ing in intravenous therapy for heart failure) or 
death from cardiovascular causes was lower in 
the dapagliflozin group than in the placebo group. 
Each of the three components of the composite 
outcome was less common in the dapagliflozin 
group, as were the total numbers of hospitaliza-
tions for heart failure and deaths from cardio-
vascular causes. The use of dapagliflozin also 
resulted in fewer symptoms of heart failure, as 
measured on the Kansas City Cardiomyopathy 
Questionnaire. The observed benefits, which were 
substantial and clinically significant, occurred 
early after randomization and were seen in pa-
tients who were receiving other recommended 
therapies for heart failure.
Dapagliflozin was as effective in the 55% of 
patients without type 2 diabetes as in those with 
diabetes. This demonstration of the cardiovascu-
lar benefits of an SGLT2 inhibitor in patients 
without diabetes provides support for prior sug-
gestions that such treatment has beneficial ac-
tions other than glucose lowering.4-11 Thus, our 
findings potentially extend the therapeutic role 
of dapagliflozin beyond patients with diabetes.
The lowering of the risk of the primary out-
come was generally consistent across the other 
prespecified subgroups, although one compari-
son suggested possible heterogeneity, with less 
treatment benefit in patients in NYHA functional 
class III or IV than in class II. However, findings 
with respect to other subgroups that also re-
flected more advanced disease (e.g., more reduced 
ejection fraction, worse renal function, and an 
increased NT-proBNP level) were not consistent 
with the finding regarding the NYHA class.
Our population was distinct from the patients 
in previous trials of SGLT2 inhibitors, since our 
patients were at much higher risk for hospital-
ization for heart failure and for death from car-
diovascular causes than many of the patients in 
the previous trials. Most of the patients in our 
trial were already being treated with a loop di-
uretic and a mineralocorticoid receptor antago-
nist, and we did not know whether dapagliflozin 
would cause the initial diuresis seen in other 
patient groups. We did not know whether such 
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Figure 3. Primary Composite Outcome, According to Prespecified Subgroup.
Shown is the primary outcome of the trial — a composite of hospitalization for heart failure, an urgent visit result-
ing in intravenous therapy for heart failure, or death from cardiovascular causes — according to subgroups that 
were prespecified in the protocol. Race was reported by the investigators. The body-mass index is the weight in kilo-
grams divided by the square of the height in meters. ECG denotes electrocardiography, eGFR estimated glomerular 
filtration rate, LVEF left ventricular ejection fraction, MRA mineralocorticoid receptor antagonist, NT-proBNP N-ter-
minal pro–B-type natriuretic peptide, and NYHA New York Heart Association.
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  281/1696
105/677
  215/1075
  171/1298
109/569
  277/1804
  223/1316
  163/1057
  259/1537
127/834
191/962
  195/1410
  502/2371
196/998
  306/1373
  
  406/1826
  96/545
  348/1671
  32/104
118/564
  4/32
114/553
  218/1060
  73/342
  97/416
  289/1597
213/774
  307/1239
  195/1132
  155/1179
  347/1191
  279/1127
  223/1244
  361/1674
141/697
  271/1064
  231/1307
126/559
  376/1812
  289/1358
  213/1013
  320/1533
182/838
254/964
  248/1406
no. of patients/total no.
All patients
Age
≤65 yr
>65 yr
Sex
Male
Female
Race
White
Black 
Asian
Other
Geographic region
Asia
Europe
North America
South America
NYHA class
II
III or IV
LVEF
≤Median
>Median
NT-proBNP
≤Median
>Median
Hospitalization for heart failure
Yes
No
MRA at baseline
Yes
No
Type 2 diabetes at baseline
Yes
No
Atrial fibrillation or flutter on enrollment ECG
Yes
No
Main cause of heart failure
Ischemic
Nonischemic or unknown
Body-mass index
<30
≥30
Baseline eGFR (ml/min/1.73m2)
<60
≥60
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an effect might lead to volume depletion and 
worsening of renal function, since many of our 
patients had chronic kidney disease. As it turned 
out, neither of these adverse effects was common 
(each occurring in <8% of the patients, with no 
between-group difference), and serious renal ad-
verse events were generally uncommon and sig-
nificantly less frequent in the dapagliflozin 
group. Overall, few patients stopped dapagliflozin 
or placebo because of any adverse effect (<5% of 
the patients in either treatment group). Major 
hypoglycemia was rare, as was diabetic ketoaci-
dosis, and both of these adverse events occurred 
only in patients with diabetes.
This trial has some limitations. We used spe-
cific inclusion and exclusion criteria, which may 
have limited the generalizability of our findings. 
Less than 5% of the patients were black, and rela-
tively few were very elderly with multiple coexisting 
illnesses. The baseline use of sacubitril–valsartan, 
which is more effective than renin–angiotensin 
system blockade alone at reducing the incidence 
of hospitalization for heart failure and death 
from cardiovascular causes, was low.18 However, 
the postulated mechanisms of action of SGLT2 
inhibition and neprilysin inhibition are distinct, 
and in a post hoc subgroup analysis, the benefit 
of dapagliflozin was similar in patients treated 
with sacubitril–valsartan and in those who did 
not receive such treatment.19,20
Among patients with heart failure and a re-
duced ejection fraction, those who received the 
SGLT2 inhibitor dapagliflozin had a lower risk 
of worsening heart failure or death from cardio-
vascular causes and better symptom scores than 
those who received placebo, regardless of the pres-
ence or absence of diabetes.
Supported by AstraZeneca.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
A data sharing statement provided by the authors is available 
with the full text of this article at NEJM.org.
Appendix
The authors’ full names and academic degrees are as follows: John J.V. McMurray, M.D., Scott D. Solomon, M.D., Silvio E. Inzucchi, 
M.D., Lars Køber, M.D., D.M.Sc., Mikhail N. Kosiborod, M.D., Felipe A. Martinez, M.D., Piotr Ponikowski, M.D., Ph.D., Marc S. Saba-
tine, M.D., M.P.H., Inder S. Anand, M.D., Jan Bělohlávek, M.D., Ph.D., Michael Böhm, M.D., Ph.D., Chern-En Chiang, M.D., Ph.D., 
Vijay K. Chopra, M.D., Rudolf A. de Boer, M.D., Ph.D., Akshay S. Desai, M.D., M.P.H., Mirta Diez, M.D., Jaroslaw Drozdz, M.D., Ph.D., 
Andrej Dukát, M.D., Ph.D., Junbo Ge, M.D., Jonathan G. Howlett, M.D., Tzvetana Katova, M.D., Ph.D., Masafumi Kitakaze, M.D., 
Ph.D., Charlotta E.A. Ljungman, M.D., Ph.D., Béla Merkely, M.D., Ph.D., Jose C. Nicolau, M.D., Ph.D., Eileen O’Meara, M.D., Mark C. 
Petrie, M.B., Ch.B., Pham N. Vinh, M.D., Ph.D., Morten Schou, M.D., Ph.D., Sergey Tereshchenko, M.D., Ph.D., Subodh Verma, M.D., 
Ph.D., Claes Held, M.D., Ph.D., David L. DeMets, Ph.D., Kieran F. Docherty, M.B., Ch.B., Pardeep S. Jhund, M.B., Ch.B., Ph.D., Olof 
Bengtsson, Ph. Lic., Mikaela Sjöstrand, M.D., Ph.D., and Anna-Maria Langkilde, M.D., Ph.D.
The authors’ affiliations are as follows: the BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom 
(J.J.V.M., M.C.P., K.F.D., P.S.J.); the Cardiovascular Division (S.D.S., A.S.D.) and the TIMI Study Group, Brigham and Women’s Hos-
pital and Harvard Medical School (M.S.S.) — all in Boston; Section of Endocrinology, Yale University School of Medicine, New Haven, 
CT (S.E.I.); Rigshospitalet Copenhagen University Hospital (L.K.) and the Department of Cardiology, Gentofte University Hospital (M. 
Schou), Copenhagen; the Department of Medicine, Saarland University Hospital, Homburg–Saar, Germany (M.B.); Saint Luke’s Mid 
America Heart Institute, University of Missouri, Kansas City (M.N.K.); National University of Cordoba, Cordoba (F.A.M.), and the Divi-
sion of Cardiology, Instituto Cardiovascular de Buenos Aires, Buenos Aires (M.D.) — both in Argentina; Wroclaw Medical University, 
Wroclaw (P.P.), and the Department of Cardiology, Medical University of Lodz, Lodz (J.D.) — both in Poland; the Department of Car-
diology, University of Minnesota, Minneapolis (I.S.A.); 2nd Department of Internal Medicine, Cardiovascular Medicine, General Teach-
ing Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic (J.B.); the Division of Cardiology, Taipei Veterans 
General Hospital and National Yang-Ming University, Taipei, Taiwan (C.-E.C.); the Department of Cardiology, Medanta, Gurgaon, India 
(V.K.C.); the Department of Cardiology, University Medical Center and University of Groningen, Groningen, the Netherlands (R.A.B.); 
the 5th Department of Internal Medicine, Comenius University in Bratislava, Bratislava, Slovakia (A.D.); the Department of Cardiology, 
Shanghai Institute of Cardiovascular Disease and Zhongshan Hospital Fudan University, Shanghai, China (J.G.); Cumming School of 
Medicine and Libin Cardiovascular Institute, University of Calgary, Calgary, AB (J.G.H.), the Department of Cardiology, Montreal Heart 
Institute, Montreal (E.O.), and the Division of Cardiac Surgery, St. Michael’s Hospital, University of Toronto, Toronto (S.V.) — all in 
Canada; Clinic of Cardiology, National Cardiology Hospital, Sofia, Bulgaria (T.K.); the Cardiovascular Division of Medicine, National 
Cerebral and Cardiovascular Center, Osaka, Japan (M.K.); the Department of Molecular and Clinical Medicine and Cardiology, Sahlg-
renska Academy (C.E.A.L.), and AstraZeneca (O.B., M. Sjöstrand, A.M.L.), Gothenburg, and the Department of Medical Sciences, Car-
diology, Uppsala Clinical Research Center, Uppsala University (C.H.), Uppsala — all in Sweden; the Heart and Vascular Center, Sem-
melweis University, Budapest, Hungary (B.M.); Instituto do Coracao, Hospital das Clinicas da Faculdade de Medicina, Universidade de 
São Paolo, São Paolo (J.C.N.); the Department of Internal Medicine, Tan Tao University, Tan Duc, Vietnam (P.N.V.); the Department of 
Myocardial Disease and Heart Failure, National Medical Research Center of Cardiology, Moscow (S.T.); and the Department of Biosta-
tistics and Medical Informatics, University of Wisconsin, Madison (D.L.D.).
The New England Journal of Medicine 
Downloaded from nejm.org at GLASGOW UNIVERSITY LIBRARY on September 20, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 13
Dapagliflozin in Heart Failure and Reduced Ejection Fr action
References
1. Zinman B, Wanner C, Lachin JM, et 
al. Empagliflozin, cardiovascular out-
comes, and mortality in type 2 diabetes. 
N Engl J Med 2015; 373: 2117-28.
2. Neal B, Perkovic V, Mahaffey KW, et 
al. Canaglif lozin and cardiovascular and 
renal events in type 2 diabetes. N Engl J 
Med 2017; 377: 644-57.
3. Wiviott SD, Raz I, Bonaca MP, et al. 
Dapaglif lozin and cardiovascular out-
comes in type 2 diabetes. N Engl J Med 
2019; 380: 347-57.
4. Perkovic V, Jardine MJ, Neal B, et al. 
Canaglif lozin and renal outcomes in type 
2 diabetes and nephropathy. N Engl J Med 
2019; 380: 2295-306.
5. Packer M, Anker SD, Butler J, Filippa-
tos G, Zannad F. Effects of sodium-glucose 
cotransporter 2 inhibitors for the treatment 
of patients with heart failure: proposal of a 
novel mechanism of action. JAMA Cardiol 
2017; 2: 1025-9.
6. Verma S, McMurray JJV. SGLT2 in-
hibitors and mechanisms of cardiovascu-
lar benefit: a state-of-the-art review. Dia-
betologia 2018; 61: 2108-17.
7. Inzucchi SE, Kosiborod M, Fitchett D, 
et al. Improvement in cardiovascular out-
comes with empagliflozin is independent 
of glycemic control. Circulation 2018; 138: 
1904-7.
8. Lytvyn Y, Bjornstad P, Udell JA, 
Lovshin JA, Cherney DZI. Sodium glucose 
cotransporter-2 inhibition in heart fail-
ure: potential mechanisms, clinical appli-
cations, and summary of clinical trials. 
Circulation 2017; 136: 1643-58.
9. Bonnet F, Scheen AJ. Effects of SGLT2 
inhibitors on systemic and tissue low-
grade inflammation: the potential contri-
bution to diabetes complications and car-
diovascular disease. Diabetes Metab 
2018; 44: 457-64.
10. Wanner C, Inzucchi SE, Lachin JM, et 
al. Empagliflozin and progression of kid-
ney disease in type 2 diabetes. N Engl J 
Med 2016; 375: 323-34.
11. Zelniker TA, Wiviott SD, Raz I, et al. 
SGLT2 inhibitors for primary and second-
ary prevention of cardiovascular and renal 
outcomes in type 2 diabetes: a systematic 
review and meta-analysis of cardiovascu-
lar outcome trials. Lancet 2019; 393: 31-9.
12. McMurray JJV, DeMets DL, Inzucchi 
SE, et al. A trial to evaluate the effect of 
the sodium-glucose co-transporter 2 in-
hibitor dapaglif lozin on morbidity and 
mortality in patients with heart failure 
and reduced left ventricular ejection frac-
tion (DAPA-HF). Eur J Heart Fail 2019; 21: 
665-75.
13. McMurray JJV, DeMets DL, Inzucchi 
SE, et al. The Dapaglif lozin And Preven-
tion of Adverse-outcomes in Heart Failure 
(DAPA-HF) trial: baseline characteristics. 
Eur J Heart Fail 2019 July 15 (Epub ahead 
of print).
14. Green CP, Porter CB, Bresnahan DR, 
Spertus JA. Development and evaluation 
of the Kansas City Cardiomyopathy Ques-
tionnaire: a new health status measure 
for heart failure. J Am Coll Cardiol 2000; 
35: 1245-55.
15. Hicks KA, Mahaffey KW, Mehran R, 
et al. 2017 Cardiovascular and stroke end-
point definitions for clinical trials. Circu-
lation 2018; 137: 961-72.
16. Lin DY, Wei LJ, Yang I, Ying Z. Semi-
parametric regression for the mean and 
rate functions of recurrent events. J R Stat 
Soc Series B Stat Methodol 2000; 62: 711-
30.
17. Wang D, Pocock S. A win ratio ap-
proach to comparing continuous non-
normal outcomes in clinical trials. Pharm 
Stat 2016; 15: 238-45.
18. McMurray JJV, Packer M, Desai AS, et 
al. Angiotensin–neprilysin inhibition ver-
sus enalapril in heart failure. N Engl J 
Med 2014; 371: 993-1004.
19. McMurray JJ. Neprilysin inhibition to 
treat heart failure: a tale of science, seren-
dipity, and second chances. Eur J Heart 
Fail 2015; 17: 242-7.
20. Packer M. Reconceptualization of the 
molecular mechanism by which sodium-
glucose cotransporter 2 inhibitors reduce 
the risk of heart failure events. Circula-
tion 2019; 140: 443-5.
Copyright © 2019 Massachusetts Medical Society.
The New England Journal of Medicine 
Downloaded from nejm.org at GLASGOW UNIVERSITY LIBRARY on September 20, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
